Clinical trial NCT02193113: A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
Official title: An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetic Macular Edema
Keywords: Diabetic Macular Edema
DME
Plasma Kallikrein inhibitor
KVD001
KVD001-001
Intravitreal
IVT
Diabetes mellitus
Lead sponsor: KalVista Pharmaceuticals, Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Juvenile Diabetes Research Foundation
First posted: 2014-07-17
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 1 study to investigate the safety, tolerability of the novel plasma kallikrein inhibitor, KVD001 in subjects with diabetic macular edema. The study is the first step to investigate the hypothesis that plasma kallikrein plays an important role in the disease process behind diabetic macular edema in many patients

Detailed description: The plasma kallikrein-kinin system has long been recognized as a key player in inflammatory processes, capillary leakage and angiogenesis in various organs. Recent work suggests that plasma kallikrein is central to the pathogenesis of Diabetic Macular Edema (DME) and that activation of the enzyme contributes to the excessive retinal vascular permeability leading to DME. Among different persons with DME, plasma kallikrein contributes both independently in some, and in association with Vascular Endothelial Growth Factor (VEGF) in others. However, the effect of plasma kallikrein appears to be independent of VEGF. Thus, growing scientific evidence points to plasma kallikrein inhibitors as an exciting potential new therapeutic opportunity directed at a novel VEGF-independent pathway that may reduce retinal vascular permeability and treat DME, in patients whose disease process is, at least in part, driven by the plasma kallikrein pathway.

This is an open label, single ascending dose study to investigate the safety, tolerability and pharmacodynamics of a novel plasma kallikrein inhibitor administered by intravitreal (IVT) injection in subjects with central involved diabetic macular edema and reduced vision.

Eligibility criteria: Inclusion Criteria:

1. Male or female adult subjects 18 years of age and older
2. Confirmed diagnosis of Type I or Type II diabetes mellitus
3. Best corrected visual acuity, using Early Treatment Diabetic Retinopathy Study (ETDRS) electronic visual acuity (EVA) testing, of between 20/40 and 20/400 (Snellen equivalent) in the study eye
4. Fellow eye acuity 20/80 or better measured as above with no expectation of requirement for anti-VEGF treatment in fellow eye within 2 months of study drug administration
5. Presence of central involved DME in the study eye defined as Optical Coherence Tomography (OCT) Central Subfold Thickness (CST) ≥305 µm in women and ≥320 µm in men in the study eye
6. Subjects who fulfil one of the following criteria:

   1. Subjects who have not previously received an anti-VEGF treatment and who, in the view of the Investigator, can have initiation of anti-VEGF treatment in the study eye deferred for at least 2 months following the date of anticipated study drug administration
   2. Subjects who are receiving regular anti-VEGF intravitreal injections who:

      * Have received at least 3 intravitreal injections of an anti-VEGF treatment within the last 5 months (study drug administration will be at least 6 weeks after the most recent intravitreal administration of anti-VEGF) and
      * In the view of the Investigator, can have continuation of anti-VEGF treatment in the study eye deferred for at least 2 months following the date of anticipated study drug administration
   3. Subjects who have received anti-VEGF in the past (\>3 months prior to study inclusion) but are not actively receiving treatment and who in the view of the Investigator, can have resumption of anti-VEGF or alternative treatment in the study eye deferred for at least 2 months following anticipated study drug administration
7. Subjects, who in the view of the Investigator, are not expected to require panretinal laser photocoagulation or intravitreal steroids or intraocular surgery in the study eye for at least 2 months following anticipated study drug administration
8. No prior treatment with panretinal photocoagulation or intravitreal steroid in the study eye within the previous 3 months
9. No prior treatment with systemic corticosteroids or systemic anti-VEGF therapy within the previous 3 months
10. Study participant voluntarily agrees to participate in this study and signs the Institutional Review Board (IRB) approved informed consent prior to performing any procedure

Exclusion Criteria:

1. Females who are pregnant or lactating, or expecting to become pregnant during the course of the study
2. Poorly controlled diabetes mellitus
3. Uncontrolled hypertension
4. Significant co-existing disease
5. Participation in an investigational intervention clinical study within 2 months prior to study inclusion
6. History of alcohol and/or drug abuse in the last 2 years
7. Men not willing to use appropriate birth control methods
8. Media clarity or pupillary dilation inadequate to obtain reasonable quality OCT and/or fundus image
9. Subjects employed by the Sponsor or in any relationship of dependence with the Sponsor and/or Investigator

Primary outcomes:
measure: Number of participants with Adverse Events as a measure of safety and tolerability
timeFrame: 56 days
Secondary outcomes:
measure: Measurement of KVD001 plasma levels over time following intravitreal injection (with calculation of Tmax, Cmax, AUC and t1/2)
timeFrame: 28 days
measure: Best Corrected Visual Acuity as measured by ETDRS EVA
timeFrame: 56 days
Other outcomes:
measure: Change in retinal thickness from baseline
timeFrame: 84 days
Locations:
city: Beverly Hills
country: United States
facility: Retina Vitreous Associates Medical Group
state: California
city: Indianapolis
country: United States
facility: Raj K. Maturi, MD PC
state: Indiana
city: Boston
country: United States
facility: Beetham Eye Institute
state: Massachusetts
city: West Columbia
country: United States
facility: Palmetto Retina Center
state: South Carolina
city: McAllen
country: United States
facility: Valley Retina Institute, PA
state: Texas
Study officials:
affiliation: Joslin Diabetes Center
name: Jennifer Sun, MD, MPH
role: PRINCIPAL_INVESTIGATOR
affiliation: Retina-Vitreous Associates Medical Group
name: David Boyer, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Valley Retina Institute, PA
name: Victor Gonzalez, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Midwest Eye Institute
name: Raj Maturi, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Palmetto Retina Center
name: Jack Wells, MD
role: PRINCIPAL_INVESTIGATOR
References: